Calendar

Lennar had a valid after-close date and some operational positives, including sequentially improved gross margin, lower cycle time, and a solid balance sheet, but consensus still expected EPS of $1.31 and revenue of $8.396 billion against a weak housing backdrop; the recent rebound was not enough to offset the absence of positive estimate revisions and the lack of clean accumulation.

Rejected because FedEx company IR shows fiscal fourth-quarter results were reported on June 23, 2026 and the next earnings call was scheduled for October 28, so the supplied September 16 event is not a valid pre-earnings event.

Rejected because AAR reported fiscal fourth-quarter 2026 results on July 21, 2026 and its investor-events page showed no upcoming earnings event corresponding to September 21.

AutoZone had a strong prior quarter, positive same-store sales, and a small three-month revenue-estimate improvement, but the current whisper was below consensus, EPS revisions were flat to slightly negative, the stock was down over five and twenty sessions, and the highest recent volume did not clear the 1.5x threshold on a clean accumulation day.

Thor Industries had a confirmed before-open date and some diversification support from European and supplier businesses, but EPS and revenue estimates were revised lower, management cut full-year EPS guidance, prior-quarter sales and gross margin declined, and the stock was weak into the print without verified accumulation.

KB Home had a confirmed date and a possible built-to-order operating improvement, but both EPS and revenue estimates were revised lower, prior-quarter deliveries, revenue, income, backlog, and average selling price were weak, and the stock remained sharply below late-August levels; the isolated high-volume rebound was not enough to establish an upside-surprise setup.

Rejected because Ferguson reported fiscal second-quarter 2026 results on August 10, 2026 and company materials indicated the next results were expected November 9, not September 22.

News tone is mixed: strong full-year results, dividend actions, and volume recovery contrast with weak fourth-quarter profitability. A live market snapshot on August 20 showed $81.30, down 3.3% versus the prior close, suggesting the initial reaction emphasized margin pressure. Analyst revisions and social coverage were unavailable; confidence remains moderate and monitoring-oriented.

Company-source evidence is materially constructive after the earnings release, and contemporaneous headlines described a positive market reaction. However, social, options, short-interest, employee, and post-print analyst-revision data were unavailable, so confidence remains moderate and the thesis is best treated as monitoring-oriented.

Recent company-related coverage is constructive and the deterministic score shifted positive, but coverage remains low, social data and options/short-interest data are unavailable, and no verified analyst revision or post-print reaction attribution is present. This is a positive but still monitoring-oriented earnings follow-up rather than a high-conviction re-rating thesis.

Primary-source evidence is constructive on clinical validation and milestone timing, but forward visibility remains limited. The latest verified earnings-related company source is the Aug. 13 8-K [#SEC-8K-2026-08-13]; the scheduled Aug. 19 follow-up lacks confirmed analyst revisions or a separate company transcript in the packet. Deterministic returns are negative across the 5-day through 120-day horizons, supporting a monitoring stance rather than a momentum chase. Social coverage is unavailable.

Post-print news tone is strongly positive, centered on record revenue, Data Center and Industrial strength, and the record Q4 outlook. A Bernstein upgrade headline is present, but detailed analyst revisions and exact post-release price reaction are unavailable. Social, options, short-interest, and employee-sentiment data are not covered in the packet, so conviction remains below the strength of the earnings headline.

News flow is sparse and primarily earnings-summary driven. The post-earnings price action remains weak, with the latest available quote around $0.276 and down roughly 5.6% from the prior close. Analyst revisions and options/social data are unavailable, so missing reaction data is not positive evidence. The result is a cautious monitoring setup rather than a high-conviction turnaround thesis.

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update